TD Waterhouse Canada Inc. Purchases 47,215 Shares of The Cooper Companies, Inc. $COO

TD Waterhouse Canada Inc. acquired a new stake in The Cooper Companies, Inc. (NASDAQ:COO) during the third quarter, according to its most recent filing with the SEC. The firm acquired 47,215 shares of the medical device company’s stock, valued at approximately $2,669,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Essential Partners LLC lifted its stake in shares of Cooper Companies by 23.4% in the 1st quarter. Essential Partners LLC now owns 874 shares of the medical device company’s stock worth $62,000 after acquiring an additional 166 shares during the period. SJS Investment Consulting Inc. boosted its holdings in shares of Cooper Companies by 107.5% in the first quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company’s stock valued at $26,000 after acquiring an additional 187 shares in the last quarter. Basecamp Wealth Advisors LLC boosted its holdings in shares of Cooper Companies by 20.8% in the first quarter. Basecamp Wealth Advisors LLC now owns 1,557 shares of the medical device company’s stock valued at $111,000 after acquiring an additional 268 shares in the last quarter. 4WEALTH Advisors Inc. boosted its holdings in shares of Cooper Companies by 6.2% in the first quarter. 4WEALTH Advisors Inc. now owns 4,714 shares of the medical device company’s stock valued at $327,000 after acquiring an additional 275 shares in the last quarter. Finally, Patton Fund Management Inc. increased its stake in shares of Cooper Companies by 10.0% during the first quarter. Patton Fund Management Inc. now owns 3,233 shares of the medical device company’s stock worth $231,000 after acquiring an additional 293 shares during the period. 24.39% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

COO has been the subject of several analyst reports. Wells Fargo & Company set a $61.00 price target on shares of Cooper Companies and gave the stock an “equal weight” rating in a report on Thursday, September 10th. Citigroup restated a “neutral” rating and issued a $60.00 price objective (down from $80.00) on shares of Cooper Companies in a research report on Thursday, September 10th. UBS Group lowered their price objective on Cooper Companies from $75.00 to $66.00 and set a “neutral” rating on the stock in a report on Thursday, September 10th. Mizuho set a $75.00 target price on Cooper Companies and gave the stock an “outperform” rating in a research report on Thursday, September 10th. Finally, Barclays raised Cooper Companies to a “hold” rating in a research note on Wednesday, October 7th. Four equities research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Cooper Companies presently has a consensus rating of “Hold” and a consensus price target of $68.60.

Cooper Companies Trading Up 1.7%

Shares of COO opened at $59.12 on Wednesday. The Cooper Companies, Inc. has a twelve month low of $51.01 and a twelve month high of $89.83. The company has a current ratio of 1.22, a quick ratio of 0.73 and a debt-to-equity ratio of 0.23. The firm has a market capitalization of $11.24 billion, a P/E ratio of 20.18, a PEG ratio of 2.37 and a beta of 0.83. The firm’s 50-day moving average is $62.74 and its two-hundred day moving average is $65.94.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.12 by $0.03. The company had revenue of $1.07 billion during the quarter, compared to the consensus estimate of $1.10 billion. Cooper Companies had a net margin of 13.46% and a return on equity of 10.90%. The company’s revenue for the quarter was up .5% on a year-over-year basis. During the same period last year, the firm earned $0.49 EPS. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. On average, research analysts predict that The Cooper Companies, Inc. will post 4.53 earnings per share for the current fiscal year.

Cooper Companies declared that its board has initiated a stock repurchase program on Wednesday, September 9th that permits the company to repurchase $3.00 billion in outstanding shares. This buyback authorization permits the medical device company to purchase up to 22.7% of its stock through open market purchases. Share buyback programs are typically an indication that the company’s board believes its shares are undervalued.

Insider Activity at Cooper Companies

In other news, Director Lawrence Kurzius acquired 10,000 shares of the company’s stock in a transaction that occurred on Monday, September 14th. The stock was purchased at an average cost of $53.91 per share, with a total value of $539,100.00. Following the purchase, the director directly owned 21,099 shares of the company’s stock, valued at approximately $1,137,447.09. This trade represents a 90.10% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Paul Keel acquired 4,701 shares of Cooper Companies stock in a transaction that occurred on Friday, September 11th. The shares were purchased at an average cost of $53.18 per share, with a total value of $249,999.18. Following the completion of the acquisition, the director owned 4,701 shares of the company’s stock, valued at $249,999.18. The trade was a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders bought 34,701 shares of company stock valued at $1,880,039 in the last ninety days. Corporate insiders own 2.08% of the company’s stock.

Cooper Companies Company Profile

CooperCompanies is a global medical device company that develops, manufactures and markets products for vision care and women’s health. The company operates through two primary business segments: CooperVision and CooperSurgical.

CooperVision provides contact lenses and related technologies, including products designed for myopia management, astigmatism, presbyopia and other vision-correction needs. Its portfolio includes daily disposable, reusable and specialty contact lenses sold through eye-care professionals and distributors.

CooperSurgical develops products and services for fertility and women’s health.